These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 30306859)

  • 101. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 103. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
    Hess CN; Low Wang CC; Hiatt WR
    Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 105. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 106. [Current update on PCKS9 inhibitors].
    Gencer B; Nanchen D; Collet TH; Rodondi N; Mach F
    Rev Med Suisse; 2018 Feb; 14(596):482-486. PubMed ID: 29489129
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing.
    Wang X; Musunuru K
    JACC Basic Transl Sci; 2019 Oct; 4(6):755-762. PubMed ID: 31709322
    [TBL] [Abstract][Full Text] [Related]  

  • 108. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 109. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
    King P; Nicholls SJ
    Curr Cardiol Rep; 2017 Aug; 19(8):66. PubMed ID: 28643240
    [TBL] [Abstract][Full Text] [Related]  

  • 110. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
    Pokrywka GS
    Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
    [TBL] [Abstract][Full Text] [Related]  

  • 111. PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes.
    Farmaki P; Damaskos C; Garmpis N; Garmpi A; Savvanis S; Diamantis E
    Curr Drug Discov Technol; 2020; 17(2):138-146. PubMed ID: 30526464
    [TBL] [Abstract][Full Text] [Related]  

  • 112. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD; Kim JB; Wasserman SM; Lambert G
    Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
    [TBL] [Abstract][Full Text] [Related]  

  • 113. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
    Stefanutti C; Morozzi C; Di Giacomo S
    Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 115. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 117. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
    Gaine SP; Quispe R; Patel J; Michos ED
    Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.
    Stein R; Ferrari F; Scolari F
    Curr Cardiol Rep; 2019 Jun; 21(8):68. PubMed ID: 31227920
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond.
    Wong ND; Rosenblit PD; Greenfield RS
    Cardiovasc Diagn Ther; 2017 Apr; 7(Suppl 1):S11-S20. PubMed ID: 28529918
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
    Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
    Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.